Related Experiment Video

Updated: Jan 31, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.9K

Drastic Response to Olaparib in a Patient With Metastatic Castration-Resistant Prostate Cancer Harboring BRCA2

Kotaro Yokota1, Takeo Kosaka1, Tatsuaki Daimon2

  • 1Department of Urology Keio University School of Medicine Tokyo Japan.

IJU Case Reports
|January 30, 2026
PubMed
Abstract

Insights

This study presents a prostate cancer case with BRCA2 mutation and high tumor mutational burden (TMB-H). Olaparib treatment showed significant response in metastatic castration-resistant prostate cancer (CRPC).

Area of Science:

  • Oncology
  • Genetics
  • Medical Research

Background:

  • Prostate cancer can be driven by BRCA2 alterations and high tumor mutational burden (TMB-H).
  • The co-occurrence of these biomarkers is rare.
  • Limited evidence exists for PARP inhibition in castration-sensitive prostate cancer.

Purpose of the Study:

  • To describe a case of metastatic castration-resistant prostate cancer (CRPC) with both BRCA2 mutation and TMB-H.
  • To evaluate the response to olaparib in a patient with these specific biomarkers.

Main Methods:

  • A 74-year-old male patient with metastatic CRPC was analyzed.
  • Genomic profiling identified a pathogenic BRCA2 mutation and near-threshold TMB.
  • The patient received olaparib treatment after initial chemohormonal therapy was discontinued.

Main Results:

  • The patient showed a marked response to olaparib.
  • Radiological imaging revealed regression of primary and nodal disease.
  • Prostate-specific antigen (PSA) and SCC levels decreased significantly over 3 months.

Conclusions:

  • Olaparib demonstrated efficacy in metastatic CRPC with BRCA2 mutation and near-threshold TMB.
  • The findings suggest potential benefit of PARP inhibition in such cases.
  • Further research is warranted for PARP inhibitors in advanced prostate cancer settings.
Keywords:
BRCA mutationTMB‐Hnear‐threshold TMBprostate cancer

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.2K
Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells08:03

Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells

Published on: October 20, 2015

14.6K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Mutations01:39

Mutations

Overview
94.5K
Mutations01:35

Mutations

Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
44.5K
Viral Mutations00:36

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.9K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.9K
Alterations in Respiration II01:30

Alterations in Respiration II

There are numerous types of normal and abnormal respiration. Based on ventilatory movements, breathing patterns are classified as regular, deep, or shallow. Examples include Biot's breathing, Cheyne-Stokes respiration, Kussmaul's breathing, hyperventilation, and hypoventilation. Each pattern is clinically significant and aids in evaluating patients.
In Biot's breathing, the respiratory rate and depth are irregular, alternating between periods of deep gasping and apnea. Common causes...
1.8K